Across TCGA pan-cancer cohorts, FZD3 mass-spec protein is linked to patient survival in 2 of 34 cancer types, making it a survival-associated FZD3 data layer compared with 19 for mass-spec protein and 6 for mutation status.
The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher FZD3 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated FZD3 expression acts as an unfavorable survival marker, although some lineages such as GBM show a favorable association.
UCEC and GBM are the cancer types where FZD3 mass-spec protein most reproducibly stratifies survival.